Salute e Benessere

Buyback of Class B shares in Essity during week 34, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
26/08/2024

Kanazawa University research: High-speed atomic force microscopy reveals dynamic…

The team employed an advanced imaging technique known as high-speed atomic force microscopy (HS-AFM) to observe the real-time behavior of the N-terminal domain (NTD) in the GluA2 subunit. The NTD is the starting segment of the protein, playing a critical role in how AMPARs function and cluster at synapses. The study also examined how the GluA2 subunit interacts with TARP γ2, a regulatory protein that fine-tunes the receptor's response to signals. The team employed an advanced imaging…
PR Newswire
26/08/2024

KFSHRC Pioneers Solutions to Overcome Medical Education Challenges

RIYADH, Saudi Arabia, Aug.26, 2024(GLOBE NEWSWIRE) -- Medical trainees encounter numerous challenges, such as managing rigorous training demands, accessing relevant, state-of-the-art resources, and coping with the high-pressure environment of medical education. Recognizing these hurdles, King Faisal Specialist Hospital & Research Centre (KFSHRC) has implemented strategic initiatives such as the King Faisal Aspiring Research Program (KARP), which provides high-level mentorship and...
Nasdaq GlobeNewswire
26/08/2024

Cessatech and Proveca announce world-wide excluding US commercial partnership…

There is a large unmet need for acute pain management in children. Despite the many pain-relieving products available for adults, few of these have been developed for children. A study on unlicensed drug prescription revealed that as much as 70 percent of all medications for children currently prescribed in hospital settings are administered off-label, meaning that the use deviates from the approved and intended dose, is not clinically validated, documented, or approved for children. In Europe…
PR Newswire
26/08/2024

SIFI Receives European Commission Approval for AKANTIOR®

AK is an ultra-rare, severe, progressive and sight threatening corneal infection characterized by intense pain and photophobia. AK is caused by a free-living amoeba, acanthamoeba, and primarily affects contact lens wearers. AK is an ultra-rare, severe, progressive and sight threatening corneal infection characterized by intense pain and photophobia. AK is caused by a free-living amoeba, acanthamoeba, and primarily affects contact lens wearers. "Today's approval represents an important…
PR Newswire
26/08/2024

Innovative Training and Simulation Propel KFSHRC to Global Leadership in Medical…

RIYADH, Saudi Arabia, Aug.25, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is revolutionizing clinical training through its iLearn Portal and comprehensive simulation-based programs in a bold move towards excellence in medical education and training. KFSHRC's simulation training initiatives utilize virtual reality (VR) and scenario-based learning to offer hands-on experience in a controlled environment, preparing healthcare professionals for...
Nasdaq GlobeNewswire
25/08/2024

KFSHRC Sets New Global Standards in Digital Healthcare Education

RIYADH, Saudi Arabia, Aug.24, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is leveraging innovative technologies to enhance medical education and training, rolling out ground-breaking initiatives such as the Smart On-Call Room and the Virtual Science Library.The Smart On-Call Room, powered by STID Mobile ID, has real-time access to critical information, including patient records and clinical guidelines. Streamlining on-call responsibilities...
Nasdaq GlobeNewswire
24/08/2024

Fagron's share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 23 August 2024 – 6PM CET Fagron's share buy-back program: Weekly update In the period from 19 August 2024 through 23 August 2024, Fagron purchased 34,500 of its owns shares at an average price of € 18.99 per share corresponding to a total amount of € 655,081.09. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron's obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
23/08/2024

Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis

Søren Tulstrup, President and CEO, Hansa Biopharma remarked, "Matt has been a fantastic addition to the Hansa executive team and has made significant contributions across the organization over the past years. I want to thank Matt for his commitment and dedication to advancing key priorities including commercialization efforts in Europe, acceleration of our ConfIdeS US pivotal study, and the initiation of launch planning in the US, and we wish him well in his new endeavor. Søren Tulstrup,...
PR Newswire
23/08/2024

Report of transactions of shares and related securities of Bavarian Nordic by…

COPENHAGEN, Denmark, August 23, 2024– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NameKaren Merete Jensen 2.Reason for the notification a)Position/statusMember of the Board...
Nasdaq GlobeNewswire
23/08/2024

Ablation Technology Market worth $9.62 billion by 2029 driven by Emerging Tech…

Browse in-depth TOC on "Ablation Technology Market" Browse in-depth TOC on "Ablation Technology Market" 226 - Tables 64 - Figures 290 - Pages Johnson & Johnson: Innovator in Ablation Technology Johnson & Johnson (US) is a prominent player in the ablation technology market through its subsidiaries, Ethicon Inc. and Biosense Webster, Inc. The company specializes in pulsed field ablation platforms and therapeutic catheters. To expand its portfolio, Johnson &...
PR Newswire
23/08/2024

Essential Oils Market Surges to USD 40.12 Billion by 2030, Propelled by 7.9%…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=31712 Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=31712 Browse in-depth TOC onEssential Oils Market 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Global Essential Oils Market Overview Market Drivers Fueling Growth in the Essential Oils Market Rising Consumer Demand for Natural Products:The increasing preference for natural and...
PR Newswire
23/08/2024

Vistin Pharma ASA: Mandatory notification of trade

Saga Pure ASA has on 23 August 2024 purchased 300,000 shares in Vistin Pharma ASA at NOK 22,50 per share. After the transaction Saga Pure ASA has a holding of 400,000 shares, corresponding to 0.9 % ownership. Saga Pure ASA is closely associated with board member Øystein Stray Spetalen. Attachment 20240823_Notification of trade_Saga i Vistin
Nasdaq GlobeNewswire
23/08/2024

Cell Counting Market is expected to generate a revenue of USD 16.5 Billion by…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=29479 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=29479 Browse in-depth TOCon" Global Cell Counting Market Size " 202 - Pages 126 – Tables 37 – Figures Report Scope Global Cell Counting Market Overview Advancements in Automated Cell Counting Technologies:The Cell Counting Market is experiencing strong expansion as a result of...
PR Newswire
23/08/2024

UTime Limited to Participate in International Medical Fairs and Medical…

In addition to MEDICA, UTime plans to attend the Cardiology Society Conference, Sleep Conference, and Hypertension Conference in the United States. These conferences gather leading medical experts and scholars, offering UTime not only a platform to present its technological advancements to the industry but also an excellent opportunity to learn and derive insights from global peers. In addition to MEDICA, UTime plans to attend the Cardiology Society Conference, Sleep Conference, and...
PR Newswire
23/08/2024

OKYO Pharma CEO Interview to Air on Bloomberg TV

LONDON and NEW YORK, Aug.23, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today an interview with its CEO, Dr. Gary S. Jacob will air on The...
Nasdaq GlobeNewswire
23/08/2024

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Aug.23, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an...
Nasdaq GlobeNewswire
23/08/2024

AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for…

Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., Aug.23, 2024(GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 trial with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME). “We have achieved a major milestone, full enrollment in our Phase 1, Safety Trial in the U.S.” said Diane Tang-Liu, PhD, CEO, President...
Nasdaq GlobeNewswire
23/08/2024

KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs

RIYADH, Saudi Arabia, Aug.23, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) solidifies its medical education and research leadership through its Academic & Training Affairs (ATA) Department, which offers structured learning, intensive workshops, and personalized mentorship.A highlight of KFSHRC's medical education is the King Faisal Aspiring Research Program, developed in partnership with the Research and Innovation Centre and Al-Faisal...
Nasdaq GlobeNewswire
23/08/2024

PCI Biotech: Invitation to first half interim 2024 results presentation

The presentation will be held as a live webcast available through www.pcibiotech.com. The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com, from 07.00am CEST the same day.For further information, please contact: Ronny Skuggedal, CEO /...
Nasdaq GlobeNewswire
23/08/2024

Invitation to presentation of Sectra's three-month interim report 2024/2025

To participate, follow the instructions on Sectra's website investor.sectra.com/q1report2425. The broadcast will be made available on the same webpage after the conference. To participate, follow the instructions on Sectra's websiteinvestor.sectra.com/q1report2425. The broadcast will be made available on the same webpage after the conference. Participation will take place via Microsoft Teams. Questions can be posed using the chat function or by sending questions in advance via email to...
PR Newswire
23/08/2024

Vistin Pharma ASA: Second quarter and first half 2024 financial results

rdof August 2024Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2024.Revenue in the second quarter ended at MNOK 106 compared to MNOK 107 in Q2 2023. Sales volume in the quarter was up by 4% compared to Q2 2023, currency neutral sales increased by 1%. Revenue for first half of 2024 ended at MNOK 210 compared to MNOK 208 YTD last year.Second quarter EBITDA ended at MNOK 27 compared to MNOK 20 in Q2 2023, representing a 40% increase. EBITDA...
Nasdaq GlobeNewswire
23/08/2024

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1…

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos' Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL).GLPG5101 is an autologous CD19 CAR-T cell therapy...
Nasdaq GlobeNewswire
23/08/2024

Coway Releases Its New Sustainability Report for FY2023

The New Coway Sustainability Report 2023* highlights the key achievements for 2023 in each ESG sector. The New Coway Sustainability Report 2023* highlights the key achievements for 2023 in each ESG sector. In the Environment sector, Coway's waste mattress recovery and recycling system was recognized by the Ministry of Environment as an exemplary case of resource circulation in South Korea. Coway has established a Scope 3 inventory to measure the amount of greenhouse gases generated...
PR Newswire
23/08/2024
Altri  Comunicati